Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Blood Advances|October 26, 2022
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLLNitin Jain, Jayastu Senapati, Beenu Thakral, et al.
Vaccine|August 4, 2011
Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: a test-negative case control studyAllen C Cheng, Tom Kotsimbos, Heath A Kelly, et al.
British Journal of Haematology|March 30, 2019
Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatmentsBoyu Hu, Keyur P Patel, Hsiang-Chun Chen, et al.
The New England Journal of Medicine|February 6, 2020
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid TumorsEnli Liu, David Marin, Pinaki Banerjee, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Leukemia|May 19, 2021
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrationsNitin Jain, Philip Thompson, Jan Burger, et al.
American Journal of Hematology|October 20, 2017
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphomaYasmin Abaza, Hagop M Kantarjian, Stefan Faderl, et al.
The New England Journal of Medicine|May 30, 2019
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, Michael Keating, Philip Thompson, et al.
JAMA Oncology|June 10, 2021
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 TrialNitin Jain, Michael Keating, Philip Thompson, et al.
Pageof 6